PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15137105

Fast relaxation processes and structural changes in immunoactive biomolecules.

N A Borisevich·V L Dubovsky·A L Mikhalchuk·T F Raichyonok·S A Tikhomirov·G B Tolstorozhev
View original source ↗Export metadata ↓

Abstract

Based upon an analysis of the absorption spectra, the fluorescence and fluorescence excitation spectra, and the lifetime of the excited states of aqueous solutions (pH 7.4) of 2,3-dimethoxy-8-azagona-1,3,5(10),13-tetraene-12,17-dione, it is established that two centers of different type exist: one emits long-wave (L-centers) and the other short-wave (S-centers) fluorescence. Irradiation of solutions increases the number of L-centers and greatly decreases that of S-centers. Examination of the picosecond transient absorption spectra and their kinetics revealed that the initial photochemical stage is defined as the ionization of a considered molecule and the subsequent one, as the formation, most probably, of the dehydroderivative of a parent molecule.

Explore related subjects

AzasteroidsBiopolymersDiterpenesGlassHydrogen-Ion ConcentrationIonsKineticsLasersLightModels, ChemicalProtonsSpectrophotometryTime FactorsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N A Borisevich, V L Dubovsky, A L Mikhalchuk, T F Raichyonok, S A Tikhomirov, G B Tolstorozhev. Fast relaxation processes and structural changes in immunoactive biomolecules.. https://doi.org/10.1002/bip.20054

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Delayed fluorescence and phosphorescence of 8-aza-D-homogonane in the gas and condensed phases.

The delayed fluorescence spectrum for 8-aza-D-homogonane in the gas phase consists of a band of E-type delayed fluorescence of M-centers and a band of P-type delayed fluorescence of L-centers being the products of photo- and thermotransformations of a basic steroid. Triplet-triplet energy transfer from the M-centers to the L-centers is established and its efficiency is determined. For 8-aza-D-homogonane in frozen hexane solutions at T=77 K only the phosphorescence of the M- and L-centers is revealed. The phosphorescence of the basic steroid itself (lambda(max)(phos) = 415 nm) as well as that of the M- and L-centers (lambda(max)(phos) = 498 and 532 nm, respectively) is seen in a mixture of frozen tetrahydrofuran and toluene solutions. This is evident of the fact that the basic steroid has the products of its transformations, whose amount grows due to irradiation and heating. The M- and L-centers are stable molecules.

Azasteroids↗
PubMed2006

Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, drug interactions, and dosing recommendations of dutasteride, a 5-alpha reductase inhibitor for benign prostatic hyperplasia (BPH). DATA SOURCES: A MEDLINE search (1966-February 2006) was conducted to extract human research data in the English language on dutasteride. Search terms included benign prostatic hyperplasia, dutasteride, and finasteride. The reference lists of articles identified through this search process, the manufacturer's Web site, and dutasteride prescribing information were also examined. STUDY SELECTION AND DATA EXTRACTION: All published studies and clinical data from the manufacturer were included, with emphasis placed on randomized, controlled trials. DATA SYNTHESIS: Dutasteride is approved for the treatment of symptomatic BPH in men with an enlarged prostate to improve urinary symptoms, reduce the risk of acute urinary retention, and reduce the need for BPH-related surgical interventions. Compared with placebo, dutasteride has been shown to significantly improve BPH symptoms, reduce the incidence of acute urinary retention and BPH-related surgery, and improve BPH-related quality of life. Few published data exist comparing dutasteride with finasteride. The most common adverse effects of dutasteride include ear, nose, and throat infection; malaise; headache; dizziness; and musculoskeletal pain. CONCLUSIONS: Clinical trials, sponsored primarily by the manufacturer, have shown dutasteride to be an effective treatment of BPH compared with placebo and to likely possess efficacy similar to that of finasteride. Further studies are needed to gain a more clear understanding of any clinically significant differences between dutasteride and finasteride.

Azasteroids↗